LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary to lead advancement of the LiGHT System proton therapy platform following the company's November 2025 acquisition of Liora's assets.
Actor James Van Der Beek died at age 48 from colorectal cancer, highlighting a troubling trend of rising cancer rates and deaths among younger Americans despite overall declines in older populations.
LIXTE Biotechnology Holdings appointed Sidney Braun as CEO of its Liora Technologies Europe Ltd. subsidiary on February 18, 2026. Braun brings over 20 years of healthcare experience and facilitated LIXTE's November 2025 acquisition of Liora's assets.
LIXTE Biotechnology Holdings is developing LB-100, a first-in-class PP2A inhibitor designed to enhance chemotherapy and immunotherapy effectiveness across multiple cancer types, with proof-of-concept trials underway.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07321106 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer |
RECRUITING | PHASE1 |
| NCT06929338 |
xDRIVE in Metastatic Colorectal Cancer |
NOT_YET_RECRUITING | |
| NCT06446557 |
De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer |
NOT_YET_RECRUITING | PHASE3 |
| NCT06335147 |
PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer |
NOT_YET_RECRUITING | NA |
| NCT06202183 |
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial |
RECRUITING | NA |
| NCT06180460 |
CALM: Managing Distress in Malignant Brain Cancer |
COMPLETED | NA |
| NCT05983367 |
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer |
TERMINATED | PHASE2 |
| NCT05848739 |
A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors |
RECRUITING | PHASE1 |
| NCT05714124 |
Liver Embolization Approaches for Tumor Management |
RECRUITING | |
| NCT05468892 |
Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial |
COMPLETED | PHASE2 |
